Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) shares gapped up before the market opened on Thursday . The stock had previously closed at $5.13, but opened at $5.33. Aurinia Pharmaceuticals shares last traded at $5.19, with a volume of 8,387 shares traded.
Analyst Ratings Changes
A number of analysts have commented on the stock. Royal Bank of Canada cut their price target on shares of Aurinia Pharmaceuticals from $18.00 to $10.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. HC Wainwright cut their price target on shares of Aurinia Pharmaceuticals from $26.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, November 7th. StockNews.com assumed coverage on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 12th. They issued a "hold" rating for the company. Oppenheimer cut shares of Aurinia Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Friday, November 4th. Finally, SVB Leerink cut their price target on shares of Aurinia Pharmaceuticals from $17.00 to $12.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $12.25.
Get Aurinia Pharmaceuticals alerts:Aurinia Pharmaceuticals Price Performance
The company has a market capitalization of $724.76 million, a P/E ratio of -6.14 and a beta of 0.82. The company's 50-day moving average price is $6.43 and its two-hundred day moving average price is $8.51.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
Several large investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. raised its position in shares of Aurinia Pharmaceuticals by 54.2% in the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 1,142 shares during the period. Great West Life Assurance Co. Can raised its position in shares of Aurinia Pharmaceuticals by 22.3% in the first quarter. Great West Life Assurance Co. Can now owns 6,533 shares of the biotechnology company's stock valued at $86,000 after purchasing an additional 1,192 shares during the period. Ironwood Investment Management LLC raised its position in shares of Aurinia Pharmaceuticals by 1.0% in the first quarter. Ironwood Investment Management LLC now owns 133,117 shares of the biotechnology company's stock valued at $1,648,000 after purchasing an additional 1,357 shares during the period. Ensign Peak Advisors Inc raised its position in shares of Aurinia Pharmaceuticals by 5.3% in the first quarter. Ensign Peak Advisors Inc now owns 32,710 shares of the biotechnology company's stock valued at $405,000 after purchasing an additional 1,640 shares during the period. Finally, Tcwp LLC bought a new position in shares of Aurinia Pharmaceuticals in the first quarter valued at about $25,000. 35.20% of the stock is owned by institutional investors.About Aurinia Pharmaceuticals
(Get Rating)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
Featured Stories
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.